FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134854404> ?p ?o ?g. }

• W3134854404 endingPage "33" @default.
• W3134854404 startingPage "23" @default.
• W3134854404 abstract "Rationale: Sensitization to Fel d 1 (Felis domesticus allergen 1) contributes to persistent allergic rhinitis and asthma. Existing treatment options for cat allergy, including allergen immunotherapy, are only moderately effective, and allergen immunotherapy has limited use because of safety concerns. Objectives: To explore the relationship among the pharmacokinetic, clinical, and immunological effects of anti–Fel d 1 monoclonal antibodies (REGN1908–1909) in patients after treatment. Methods: Patients received REGN1908–1909 (n = 36) or a placebo (n = 37) in a phase 1b study. Fel d 1–induced basophil and IgE-facilitated allergen binding responses were evaluated at baseline and Days 8, 29, and 85. Cytokine and chemokine concentrations in nasal fluids were measured, and REGN1908–1909 inhibition of allergen–IgE binding in patient serum was evaluated. Measurements and Main Results: Peak serum drug concentrations were concordant with maximal observed clinical response. The anti–Fel d 1 IgE/cat dander IgE ratio in pretreatment serum correlated with Total Nasal Symptom Score improvement. The allergen-neutralizing capacity of REGN1908–1909 was observed in serum and nasal fluid and was detected in an inhibition assay. Type 2 cytokines (IL-4, IL-5, and IL-13) and chemokines (CCL17/TARC, CCL5/RANTES [regulated upon activation, normal T-cell expressed and secreted]) in nasal fluid were inhibited in REGN1908–1909–treated patients compared with placebo (P < 0.05 for all); IL-13 and IL-5 concentrations correlated with Total Nasal Symptom Score improvement. Ex vivo assays demonstrated that REGN1908 and REGN1909 combined were more potent than each alone for inhibiting FcεRI- and FcεRII (CD23)–mediated allergic responses and subsequent T-cell activation. Conclusions: A single, passive-dose administration of Fel d 1–neutralizing IgG antibodies improved nasal symptoms in cat-allergic patients and was underscored by suppression of FcεRI-, FcεRII-, and T-helper cell type 2–mediated allergic responses. Clinical trial registered with www.clinicaltrials.gov (NCT02127801)" @default.
• W3134854404 created "2021-03-15" @default.
• W3134854404 creator A5011069925 @default.
• W3134854404 creator A5016802637 @default.
• W3134854404 creator A5018894996 @default.
• W3134854404 creator A5020622830 @default.
• W3134854404 creator A5022486443 @default.
• W3134854404 creator A5031223079 @default.
• W3134854404 creator A5033935955 @default.
• W3134854404 creator A5043192106 @default.
• W3134854404 creator A5050790814 @default.
• W3134854404 creator A5054821577 @default.
• W3134854404 creator A5058562127 @default.
• W3134854404 creator A5063862530 @default.
• W3134854404 creator A5067976435 @default.
• W3134854404 creator A5073520094 @default.
• W3134854404 creator A5076795570 @default.
• W3134854404 creator A5077126049 @default.
• W3134854404 creator A5083524146 @default.
• W3134854404 creator A5085672493 @default.
• W3134854404 creator A5087967667 @default.
• W3134854404 date "2021-07-01" @default.
• W3134854404 modified "2023-10-01" @default.
• W3134854404 title "Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial" @default.
• W3134854404 cites W1577022278 @default.
• W3134854404 cites W1963954205 @default.
• W3134854404 cites W1967883194 @default.
• W3134854404 cites W1973688027 @default.
• W3134854404 cites W1974675198 @default.
• W3134854404 cites W1979432463 @default.
• W3134854404 cites W1982645716 @default.
• W3134854404 cites W1983695621 @default.
• W3134854404 cites W1984973837 @default.
• W3134854404 cites W1986235780 @default.
• W3134854404 cites W1995211939 @default.
• W3134854404 cites W2010744820 @default.
• W3134854404 cites W2011998584 @default.
• W3134854404 cites W2013908818 @default.
• W3134854404 cites W2027932154 @default.
• W3134854404 cites W2049540404 @default.
• W3134854404 cites W2049991425 @default.
• W3134854404 cites W2065201121 @default.
• W3134854404 cites W2069342459 @default.
• W3134854404 cites W2080889071 @default.
• W3134854404 cites W2089658906 @default.
• W3134854404 cites W2104772500 @default.
• W3134854404 cites W2107074680 @default.
• W3134854404 cites W2108868985 @default.
• W3134854404 cites W2110065044 @default.
• W3134854404 cites W2114053541 @default.
• W3134854404 cites W2118967511 @default.
• W3134854404 cites W2166467474 @default.
• W3134854404 cites W2199433998 @default.
• W3134854404 cites W2237993282 @default.
• W3134854404 cites W2285725215 @default.
• W3134854404 cites W2585773786 @default.
• W3134854404 cites W2614843288 @default.
• W3134854404 cites W2766144354 @default.
• W3134854404 cites W2773607015 @default.
• W3134854404 cites W2788581991 @default.
• W3134854404 cites W2793187157 @default.
• W3134854404 cites W2797705783 @default.
• W3134854404 cites W2805341017 @default.
• W3134854404 cites W2810495272 @default.
• W3134854404 cites W2890925318 @default.
• W3134854404 cites W4322574974 @default.
• W3134854404 doi "https://doi.org/10.1164/rccm.202011-4107oc" @default.
• W3134854404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8437124" @default.
• W3134854404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33651675" @default.
• W3134854404 hasPublicationYear "2021" @default.
• W3134854404 type Work @default.
• W3134854404 sameAs 3134854404 @default.
• W3134854404 citedByCount "34" @default.
• W3134854404 countsByYear W31348544042021 @default.
• W3134854404 countsByYear W31348544042022 @default.
• W3134854404 countsByYear W31348544042023 @default.
• W3134854404 crossrefType "journal-article" @default.
• W3134854404 hasAuthorship W3134854404A5011069925 @default.
• W3134854404 hasAuthorship W3134854404A5016802637 @default.
• W3134854404 hasAuthorship W3134854404A5018894996 @default.
• W3134854404 hasAuthorship W3134854404A5020622830 @default.
• W3134854404 hasAuthorship W3134854404A5022486443 @default.
• W3134854404 hasAuthorship W3134854404A5031223079 @default.
• W3134854404 hasAuthorship W3134854404A5033935955 @default.
• W3134854404 hasAuthorship W3134854404A5043192106 @default.
• W3134854404 hasAuthorship W3134854404A5050790814 @default.
• W3134854404 hasAuthorship W3134854404A5054821577 @default.
• W3134854404 hasAuthorship W3134854404A5058562127 @default.
• W3134854404 hasAuthorship W3134854404A5063862530 @default.
• W3134854404 hasAuthorship W3134854404A5067976435 @default.
• W3134854404 hasAuthorship W3134854404A5073520094 @default.
• W3134854404 hasAuthorship W3134854404A5076795570 @default.
• W3134854404 hasAuthorship W3134854404A5077126049 @default.
• W3134854404 hasAuthorship W3134854404A5083524146 @default.
• W3134854404 hasAuthorship W3134854404A5085672493 @default.
• W3134854404 hasAuthorship W3134854404A5087967667 @default.
• W3134854404 hasBestOaLocation W31348544041 @default.
• W3134854404 hasConcept C141105273 @default.

• next